<DOC>
	<DOCNO>NCT01703910</DOCNO>
	<brief_summary>The purpose study assess feasibility select personalized therapy colon cancer patient fail standard treatment , use new methodology base determination profile chemosensitivity comprehensive genetic expression analysis tumor sample .</brief_summary>
	<brief_title>Study Individualized Therapies Selection Patients With Metastatic Colorectal Carcinoma According Therapeutic</brief_title>
	<detailed_description>It prospective , randomized study patient metastatic colorectal carcinoma progress two line prior therapy . Patients randomize ( 1:1 ) receive chemotherapy determine oncologist treatment accord chemosensitivity profile obtain . For obtain profile histological tumor sample sample venous blood tube heparin standard necessary . This latter sample process isolate circulating tumor cell cell adhesion matrix coat glass sphere . The RNA circulate tumor cell well tumor cell tumor biopsy patient extract standard procedure extract RNA genetic expression analysis . Based analysis perform tumor biopsy generate ranked list potentially effective treatment every case</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histological examination show metastatic colon carcinoma . Patients 18 year . Measurable disease accord RECIST 1.1 criteriso Life expectancymore 3 month accord criterion investigator . Goodoverall condition determine ECOG scale ( score 01 ) Candidate systemic treatment base profile sensibility drug determine genetic analysis tumor sample . Patients receive least two line standard treatment , include therapy antiEGFR case tumor Kras oncogene BRaf native ( nonmutated ) . Availability tumor tissue potential tumor biopsy correlation allow RNA expression profile obtain peripheral blood CTCs . Adequate hematologic function : ANCmore 1.5 x 103 / L , platelet count absolute 100 x 109 / L , normal value INR PTT . Adequate liver function : total serum bilirubin 2 mg / dL , ALT AST 3 time upper limit establish laboratory ( LSR ) 5 LSR patient liver metastasis . Adequate renal function : serum creatinine 1.5 LSR calculate creatinine clearance 60 ml / min ( Crock ) . The patient receive systemic cancer treatment within two week prior extraction blood sample . Patient receive therapeutic radioisotope strontium 89 within 4 week blood extraction . Patient major surgery percutaneous procedure placement central venous catheter within 2 week prior blood draw . Patient history bone marrow transplantation / stem cell transplantation . Patient follow concomitant disease current condition : chronic active liver disease origin , / cirrhosis ChildPugh score B C. Uncontrolled active infection . carry human immunodeficiency virus ( HIV ) . Any significant disease opinion investigator , substantially increase risk associate patient participation study . document symptomatic brain metastasis , progression require corticosteroid associate leptomeningeal involvement . Patients uncontrolled systemic disease . Patients Hypertension Diabetes Mellitus countable time inclusion deem medically control . Patients inability oral drug delivery , either prevent gastrointestinal administration situation severe impairment intestinal absorption Any medical psychiatric condition , opinion investigator , may limit patient 's ability understand fulfill requirement partcipaci√≥n study . Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Genomic expression profile tumor sample</keyword>
	<keyword>Adult patient</keyword>
	<keyword>metastatic disease status progression two line systemic therapy</keyword>
</DOC>